在卡铂Ⅱ～Ⅲ期临床试验中，用ＣＥＡ（ＣＢＰ、ＶＰ１６、ＡＤＭ）和ＥＡＰ（ＶＰ１６、ＡＤＭ、ＤＤＰ）方案治疗非小细胞肺癌５５例，其中首治４１例，复治１４例。ＥＡＰ组常规加用地塞米松和灭吐灵防治呕吐。结果：ＣＥＡ组３１例有效率（ＣＲ＋ＰＲ）３２．２％，１年生存率３８．７％；ＥＡＰ组２４例，有效率３３．３％，１年生存率３３．３％。两组疗效无显著差异（Ｐ＞０．０５），血液毒性和呕吐发生率两组无显著差异（Ｐ＞０．０５）。 In the phase II-III clinical trials of carboplatin, 55 patients with non-small cell lung cancer were treated with CEA (CBP, VP16, ADM) and EAP (VP16, ADM, DDP) regimens, 41 of them were treated first, and 14 were retreated. The EAP group routinely added dexamethasone and metoclopramide to prevent vomiting. Results: In the CEA group, 31 cases had an effective rate (CR+PR) of 32.2%, a 1-year survival rate of 38.7%, and 24 cases of the EAP group had an effective rate of 33.3%. The 1-year survival rate was 33.3%. There was no significant difference in efficacy between the two groups (P>0.05). There was no significant difference in the incidence of hematologic toxicity and vomiting between the two groups (P>0.05).